Drug Profile

Research programme: neurodegenerative disorders therapeutics - NewcelX

Alternative Names: NLS-5/COP2Q; NLS-6/COP5F; NLS-7/COP SF

Latest Information Update: 05 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroLifeSciences
Developer NewcelX
Class Antidementias; Antiparkinsonians; Quinolines; Quinoxalines; Tryptamines
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

No development reported Huntington's disease; Lewy body disease; Parkinson's disease

30 Oct 2025 Kadimastem has merged with NLS Pharmaceutics Ltd to form NewcelX
28 Jul 2022 No recent reports of development identified for preclinical development in Huntington's-disease in Switzerland
28 Jul 2022 No recent reports of development identified for preclinical development in Lewy body disease in Switzerland

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com